51 results about "Intragastric administration" patented technology

The invention relates to a method for constructing a male non-human animal nicotine exposure model, which comprises the following steps: dissolving and extracting contents in a nicotine bag to obtain a nicotine bag content extracting solution; and selecting a male non-human animal, and performing intragastric administration with the nicotine bag content extracting solution to construct the male non-human animal nicotine exposure model. The invention also relates to a nicotine pocket reproductive development safety evaluation method based on the male non-human animal. The method comprises the following steps: taking the male non-human animal nicotine exposure model as a male parent to mate with a normal female non-human animal to generate a filial generation; detecting a parent reproduction index and a filial generation development index; and performing nicotine pocket reproductive development safety evaluation according to the male parent reproductive index and the offspring development index. The nicotine bag reproductive development safety evaluation comprises comparison with a nicotine bag safety standard substance.

The application provides a starch-indole acid derivative and a preparation method and application thereof, and relates to the technical field of modified starches. The starch-indole acid derivative refers to esterified starch generated by esterification reaction of starch, a condensing agent and alkali and indole acid. The starch-indole acid derivative has high resistance and can resist degradation of the stomach and small intestine. After reaching the colon site, the starch-indole acid derivative can be fermented by intestinal flora to release indole acid beneficial to intestinal health. Compared with traditional drug delivery modes such as intragastric administration and intraperitoneal injection, the starch-indole acid derivative has obvious advantages and can significantly increase the content of indole acid in the colon and hepatic portal vein blood. In addition, indole acid can activate an aromatic hydrocarbon receptor to play an immunoregulatory role. The immunoregulatory role of indole acid is superimposed on the regulation role of short-chain fatty acids released by starch fermentation by intestinal flora, so that a product playing an immunoregulatory role through multiple immune system signal pathways is provided.

The invention discloses application of gentiopicroside in preparation of a medicine for improving liver fatty degeneration and ferroptosis of type 2 diabetes mellitus, and belongs to the technical field of medicines. A C57BL / 6J mouse T2DM model induced by combination of high-fat feed and streptozotocin is taken as a research object, gentiopicroside is given for 8 weeks through oral administration and intragastric administration, metabolic indexes such as blood sugar, body weight, food intake and water intake of the mouse are dynamically monitored, serum and liver tissue are reserved after the mouse is killed, and the mouse can be used for preparing the gentiopicroside-gentiopicroside-gentiopicroside-gentiopicroside-gentiopicroside-gentiopicroside. Through liver pathological staining, serum and liver tissue oxidative stress index detection and PI3K / AKT / Nrf2 signal channel and ferroptosis related protein expression analysis, the pharmacological action of the gentiopicroside on T2DM is systematically evaluated, the regulation effect of the gentiopicroside on T2DM liver fatty degeneration and ferroptosis is determined for the first time, the research blank of the action mechanism of the gentiopicroside in T2DM liver complications is filled, and the application prospect of the gentiopicroside in T2DM liver complications is broadened. An experimental basis is provided for developing a novel medicine for improving T2DM liver fatty degeneration and ferroptosis.

The invention relates to genetic engineering combined lactobacillus salivarius and application of the genetic engineering combined lactobacillus salivarius. The strain is classified and named as combined lactobacillus salivarius CTMT2, and the preservation number of the strain is CCTCC (China Center for Type Culture Collection) M 2025547. After an NIAAA model is injected into the stomach of an alcoholic liver mouse, the acetaldehyde level of the liver of the mouse is obviously reduced, and the alcoholic fatty liver symptom of the mouse is obviously relieved; after long-term intragastric administration of a high-glucose and high-fat modeling mouse, the acetaldehyde level in excrement of the mouse can be obviously reduced, the progress of liver fibrosis is improved, and good application prospects are achieved.

The invention provides a preparation method of a cholestatic liver injury animal model, which comprises the following steps: on the basis that a mouse is fed with a feed containing 500IU / kg vitamin A for 8 weeks to cause deficiency of vitamin A in the mouse body, performing intragastric administration of alpha-naphthyl isothiocyanate (ANIT) at 50mg / kg for 4 weeks once a week, so as to obtain the cholestatic liver injury mouse model. The blood biochemical index ALT, the liver index, the pathological structure change of the liver tissue and the bile acid deposition of the liver tissue are more obvious. The cholestatic liver injury model prepared by the preparation method can avoid the influence of inconsistent dosage and unstable model in a conventional method, and can be applied to the research fields of molecular mechanism research of occurrence and development of cholestatic liver injury, finding of cholestatic liver injury treatment medicines and methods and the like.

The invention belongs to the technical field of animal model construction, and particularly provides a construction method and application of a mouse non-alcoholic fatty liver model, and the construction method comprises the following steps: S1, selecting an experimental mouse; s2, a high nitrogen compound aqueous solution with the mass concentration of 4-10 mg / mL is prepared; s3, according to the dosage, the dosage and the administration time, the prepared high-nitrogen compound aqueous solution is fed through the intragastric administration, and the non-alcoholic fatty liver animal model is obtained, the problems that an existing non-alcoholic fatty liver animal model is long in modeling time and expensive in modeling are solved, and the non-alcoholic fatty liver animal model does not need to be fed with high-fat feed, and is simple, convenient and feasible, low in cost, good in repeatability and stable; the establishment period of the non-alcoholic fatty liver animal model can be effectively shortened, the time cost of the medical research of the NAFLD is greatly saved, and a good animal model is provided for researching the pathogenesis and treatment strategy of the NAFLD.

The invention discloses a tree shrew Parkinson's disease model making method which comprises the following specific steps: (1) Macrozam preparation: weighing required Macrozam under a sterile condition, and dissolving the Macrozam in sterilized ultrapure water to prepare a Macrozam working solution with the concentration of 10 mg / mL; (2) gavage: gavage is conducted on the tree shrew with Macrozamine using liquid, the dosage is 40-80 mg / kg according to the mass of the tree shrew body, and a stable tree shrew Parkinson's disease model is established after normal feeding is conducted for two weeks. According to the method, the tree shrew is subjected to intragastric administration with Macrozamine, the dosage is 40-80 mg / kg, and a stable tree shrew Parkinson's disease model can be established after two weeks. According to the scheme, three transformation medical bottlenecks of a traditional model are overcome for the first time through tree shrew nigra-striatum pathway anatomy conservative property, oral transformation advantage and dosage precise control three-dimensional innovation: (1) whole course simulation; (2) channel-level fidelity; and (3) high-value prediction. The model provides an irreplaceable standardized platform for Parkinson's disease mechanism research and clinical transformation.

The invention discloses a preparation method of a gastrointestinal flatulence mouse model, which comprises the following steps: firstly, uniformly mixing a double contrast aerogenesis agent with a solvent to prepare a suspension, and performing mouse intragastric administration to give the suspension to prepare the gastrointestinal flatulence model; and after the modeling succeeds, performing double-index defoaming effect evaluation on the mouse intragastric defoaming agent by adopting the hiccup frequency of the mouse and the volume of gas in the stomach of the mouse. The invention provides a novel modeling method, clinical gastrointestinal flatulence is simulated through chemical induction and oil retention, a basic technology commonly used in a laboratory is adopted, operation is simple and easy to implement, double-index evaluation is adopted, operation or other invasive operation is not needed, animal pain and ethical dispute are remarkably reduced, and the method is suitable for large-scale popularization and application. The method directly promotes the research and development process of the defoaming agent.

The invention discloses a preparation method for constructing a mouse embryo implantation failure model based on fusobacterium variabilis, and belongs to the technical field of animal models. The method comprises the following steps: carrying out anaerobic culture on fusobacterium varium, giving the fusobacterium varium to a female C57 mouse through an intragastric administration way, continuously treating for 28 days, and inducing the female C57 mouse to have a phenotype that the number of implanted embryos is reduced and the expression of a vascular endothelial growth factor (VEGF) in a uterine tissue is reduced. According to the method, embryo implantation failure caused by intestinal flora imbalance is simulated through the'intestine-uterus axis' for the first time, a reliable animal model is provided for studying the causal relationship between flora and pregnancy failure, and the method has important scientific research and clinical application value.

The present application provides a probiotic compound preparation, which is prepared by directly mixing a probiotic compound colony dry powder with inorganic material, wherein the inorganic material is inorganic mineral material subjected to dispersion treatment; and provides a preparation method and application thereof.The probiotic compound preparation provided by the present application can play a role through simple methods such as oral administration and intragastric administration.The inorganic mineral material subjected to dispersion treatment can effectively improve its carrying capacity and colonization capacity, and can also change the microenvironment in the host body through the inorganic mineral material itself, so as to achieve the purpose of changing the composition and quantity of intestinal microflora, and then through the change of the composition and quantity of intestinal microflora, the purpose of preventing, relieving and treating various diseases caused by intestinal flora imbalance can be achieved.

The invention discloses an application of isolithocholic acid in preparation of a medicine for preventing or treating colorectal cancer induced by high fat diet. The invention proves that the isolithocholic acid can be accurately replenished by intragastric administration of 100g / kg of isoLCA at one time, and meanwhile, the isolithocholic acid can obviously inhibit the occurrence of obesity-related colon tumors, reduce the proliferation index of tumor cells and repair the intestinal barrier structure. Isolithocholic acid is endogenous secondary bile acid, can be chemically synthesized or semi-synthesized, is high in safety and good in patient compliance through oral administration, is expected to reduce the occurrence rate of colorectal cancer of obese people, and has important significance in treatment of colorectal cancer.

Use of naphthoquine phosphate in preparation of a medicament for treating autoimmune diseases. It is proved in a mouse rheumatoid arthritis model that the intragastric administration of naphthoquine phosphate can remarkably ameliorate symptoms such as joint redness, swelling, and deformities and reduce the levels of antigen-specific antibodies. It is proved in a mouse systemic lupus erythematosus model that the intragastric administration of naphthoquine phosphate can remarkably reduce the levels of anti-double-stranded DNA antibodies and anti-nuclear antibodies. Pharmacodynamic and pharmacological studies prove that naphthoquine phosphate has ideal immunosuppressive activity and can be used to prepare the medicament for treating autoimmune diseases. Further provided is a pharmaceutical use of naphthoquine phosphate in the treatment and auxiliary treatment of rheumatoid arthritis or systemic lupus erythematosus. The medicament is a pharmaceutical composition consisting of a therapeutically effective amount of naphthoquine phosphate serving as an active ingredient and pharmaceutical excipients.

The invention discloses a bacterial infection and LPS induced broiler chicken liver injury model and a construction method and application thereof, and the construction method comprises the following steps: administering 10-day-old broiler chicken with Escherichia coli E.coli O78 with a preset concentration in an intragastric administration manner; after broiler chickens are subjected to intragastric administration of escherichia coli for 18 hours, an LPS solution is injected into the intraperitoneal cavity of the broiler chickens, after the LPS solution is injected for 24 hours, the broiler chicken liver injury model is obtained, when the broiler chickens are 11 days old, the broiler chickens subjected to intragastric administration of escherichia coli are subjected to intraperitoneal injection of the LPS solution, and after the LPS solution is injected for 24 hours, the broiler chicken liver injury model is obtained. The broiler chicken liver injury model is constructed by intragastric administration of avian pathogenic escherichia coli (E.coli O78) and intraperitoneal injection of LPS (2 mg / kg), the pathology of the model is highly consistent with that of clinical broiler chicken bacterial liver injury, the liver has clinical typical lesions macroscopically, liver cells are degenerative and necrotic microscopically, and a molecular pathway activation mode is consistent with that of clinical application; the model constructed by the invention realizes specific liver injury, only the liver has specific injury, multiple organ lesions such as heart, peritoneum and the like do not exist, and the model availability is high.

The invention relates to application of a horseradish tree leaf extract in preparation of fat-reducing medicines or functional foods, and belongs to the technical field of medicines. The application comprises the following steps that S1, mice are evenly divided into five groups according to the weight of the mice after being fed for one week under the conditions of constant temperature and humidity, each group comprises eight mice, and the five groups comprise a normal control Con group, a high-fat and high-cholesterol HFC model group, a low-dose moringa oleifera leaf extract L-MOL intervention group, a high-dose moringa oleifera leaf extract H-MOL intervention group and a positive drug rosiglitazone RSG intervention group; s2, except the normal control Con group, high-fat feed is administered to other groups, administration is performed in an intragastric administration mode at ten o'clock in the morning every day, the weight of the mice is observed and recorded, and continuous administration is performed for 60 days; s3, stopping taking medicine for 24 hours after the step S2, anesthetizing and sampling blood, dissecting after cervical vertebra dislocation and killing, dissecting the abdomen of the mouse, taking a picture, and recording the subcutaneous fat weight and the white fat weight of the abdomen of each group of mouse. The moringa oleifera leaf extract provided by the invention shows an excellent fat reducing effect.

The invention discloses a compound for treating osteosarcoma as well as a preparation method and application thereof. The invention belongs to the technical field of biological medicine. The compound is a 13-methyl-palmatine derivative, and has a structure as shown in the following formula. Experiments prove that the compound 13-methyl-palmatine derivative disclosed by the invention can inhibit proliferation, cloning, migration and invasion capabilities of osteosarcoma cells in vitro. An NYG mouse subcutaneous tumor-bearing experiment proves that the traditional Chinese medicine composition can obviously inhibit the growth of osteosarcoma in vivo. Compared with a positive drug (methotrexate intraperitoneal injection), the 13-methyl-palmatine derivative has a more convenient administration mode (intragastric administration), a safer administration dosage and smaller organ and biochemical index damage degree. The invention provides a new technical means for the treatment of osteosarcoma.

The invention discloses a group of immunogenic peptides with an anti-tumor immune response activating function as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The amino acid sequences of the immunogenic peptide are SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4, and the immunogenic peptide is obtained by the following steps: extracting an enterovirus-like particle (VLPs) preparation from excrement of a healthy mouse, giving the preparation to a tumor model mouse through intragastric administration, and separating and screening from ileum tissues of the mouse by using a liquid chromatography-mass spectrometry technology. The VLPs can be migrated to tumor tissues and presented as the immunogenic peptide through tumor cell MHC-I molecules, so that CD8 + T cells are efficiently activated, a tumor immune microenvironment is remodeled, and tumor growth is inhibited. Experiments show that the immunogenic peptide shows a remarkable anti-tumor effect when being used alone or combined with a PD-1 inhibitor, and the tumor inhibition rate of drug combination can reach 89.4% and is remarkably superior to that of single treatment.

The present application belongs to the technical field of animal model construction, and relates to a insomnia animal model construction method and application with the characteristics of body deficiency, fever and emotional irritability. The application of uncoupling agent as a modeling agent in the construction of insomnia animal model with the characteristics of body deficiency, fever and emotional irritability; the uncoupling agent is carbonic acid cyanide-4-trifluoromethoxy benzyl hydrazone, carbonyl cyanide m-chlorophenyl hydrazone or benzalazoline. The present application uses mice as model animals, uses uncoupling agent as a modeling agent, and suspends or dissolves the modeling agent, then gives the mice intragastric administration once a day, and lasts for 1-4 weeks, to construct a "deficiency and irritability insomnia" insomnia animal model with the characteristics of body deficiency, fever and emotional irritability. The present application has a high degree of consistency with the traditional Chinese medicine theory, and can be well used for the screening and evaluation of anti-insomnia chemical drugs, anti-insomnia traditional Chinese medicine compounds and anti-insomnia health care products.

The invention relates to the field of medicines, and particularly discloses application of bile acid in preparation of a medicine for treating osteoporosis. Research finds that the content of hyodeoxycholic acid (HDCA) in an old individual is remarkably reduced, and the bone mineral density and the bone microstructure can be improved by supplementing the HDCA. Animal experiment results show that the HDCA can significantly inhibit bone mass loss and improve bone quality through oral administration and intragastric administration, and the effect of the HDCA depends on a bile acid receptor TGR5. HDCA is provided as an active component for treating osteoporosis for the first time, and a new drug candidate and an action mechanism can be provided for prevention and treatment of osteoporosis.

The present invention provides methods for increasing the systemic bioavailability of a polypeptide therapeutic administered orally, via oral gavage, via nasogastric gavage, or intragastric administration, comprising administering the polypeptide therapeutic to the stomach of a human or non-human animal as part of one or more dosage forms together with an alginate oligomer and, optionally, a gastrointestinal permeation enhancer, wherein the one or more dosage forms do not, in addition to the polypeptide therapeutic, the alginate oligomer, and, if used, the gastrointestinal permeation enhancer, have a coating that provides substantial protection from the gastric environment. Such methods allow for the systemic treatment or prevention of diseases, conditions, or complications thereof that are responsive to or prevented by the polypeptide therapeutic via oral, oral gavage, via nasogastric gavage, or intragastric administration. Further provided are compositions comprising an alginate oligomer, a polypeptide therapeutic, and, optionally, a gastrointestinal permeation enhancer for use in such methods.

The invention belongs to the field of medicine and health, and particularly relates to application of fresh traditional Chinese medicine radix puerariae exosome-shaped vesicles P-ELNs in medicine or health food for preventing and treating irritable bowel syndrome, the P-ELNs serving as an active ingredient can improve expression of colonic intestinal mucus protein MUC2 and tight junction protein ZO-1 and improve mucous membrane barrier integrity; the inhibition of the expression level of proinflammatory factors (such as TNF-alpha, IL-6, IL-1beta and NF-kappa B) indicates that the action mechanism may involve the synergistic effect of inflammation inhibition and barrier repair. Toxicological experiments show that the P-ELNs have no toxicity after long-term intragastric administration, have no adverse effects on heart, liver, spleen, lung and kidney functions, and have good oral safety and tissue tolerance. The indications comprise anti-inflammatory treatment of active-stage UC patients; maintenance and barrier repair of patients in the UC remission period; the UC disease course is more than or equal to 8 years, and a preventive medicine is applied to high-risk people with cancerization family history and the like; the invention relates to auxiliary treatment of UC-CAC early cancerization patients.

The invention discloses a wine sample quality evaluation method based on a slow-drunkenness and quick-waking mechanism, and belongs to the field of pharmacological research of wines. The method comprises the following steps: preparing various wine samples with uniform alcoholic strength; setting a plurality of dose gradients for the wine sample, and carrying out gavage treatment on the mouse; observing whether the mice are drunk after gavage, and calculating the drunkenness ratio of each group of mice, namely the drunkenness causing rate of the group; calculating a fitting equation according to the number and the drunkenness rate of the drunkenness mice of each dose of wine sample, and determining half of the drunkenness amount of each wine sample; according to the half drunkenness amount of each wine sample, estimating the minimum dose of each wine sample for enabling all mice to enter a drunkenness state; after the multiple groups of mice are subjected to intragastric administration according to the minimum dosage of each wine sample, the intragastric administration starting time point, the time point when the gait is unstable or the falling-down somnolence occurs and the waking time point of each mouse are recorded, and the drunkenness time and the sobering time of each wine sample are calculated; and evaluating the quality of various wine samples according to the drunkenness time and the sobering time.

The invention relates to the related technical field of moringa oleifera leaves, and discloses a method for reducing the uric acid level of a hyperuricemia mouse by a moringa oleifera leaf extract and determining the mechanism of the moringa oleifera leaf extract, and the method comprises the following steps: S1, preparing the moringa oleifera leaf extract: obtaining moringa oleifera leaf alcohol extracts with different concentrations; s2, establishing an animal model: randomly grouping mice; s3, performing a drug intervention experiment: performing intragastric administration on the moringa oleifera leaf extract in different doses to a hyperuricemia mouse, and continuously performing administration for 7 days; s4, biochemical index detection: sampling the mice, and detecting related index data of each group of mice; s5, data analysis: verifying the effect of the moringa oleifera leaf extract. According to the method, toxic and side effects are remarkably reduced, and research proves that the moringa oleifera leaf extract has good safety characteristics. The natural component structure reduces the risk of causing anaphylactic reaction, and the influence on liver and kidney functions is obviously smaller than that of chemically synthesized drugs. And no serious adverse reaction is caused after long-term use, so that a safer treatment choice is provided for gout patients.

The invention belongs to the technical field of animal model establishment, and discloses an establishment method and application of a chronic oral ferric citrate induced Parkinson mouse model, C57BL / 6 mice are fed with mouse maintenance food (high-iron feed) added with 2.25% ferric citrate for 22 weeks, and then a 5% ferric citrate solution is used for intragastric administration for 4 weeks. Finally, behavioral evaluation is carried out through behavioral tests such as an open field test, a rotating rod test, a pole climbing test, a holding power test and a Y labyrinth test, and the tests such as the rotating rod test, the pole climbing test and the holding power test show that the PD model mouse has remarkable motor function impairment such as reduction of motor coordination, muscular tension and balance force; open field tests and Y maze show that learning and memory functions of mice are impaired, and cognitive impairments such as anxiety mood occur. Clinical chronic disease conditions of Parkinson's disease are simulated, and the chronic model is more suitable for monitoring early changes and screening early diagnosis indexes of Parkinson's disease; the method has the characteristics that the behavioral disorder can be quantified, and DA energy neuron degeneration loss characteristic lesion is realized.

The invention discloses a construction method and application of a fetal ovarian reserve function reduction animal model based on an HDAC1 / USP9X pathway. According to the fetal-derived ovarian reserve function reduction model, 20 mg / kg of aspirin is given to rodents (such as Kunming mice) through intragastric administration in 9-18 days of pregnancy, and typical ovarian reserve function reduction occurs after female offspring birth. Based on an in-vitro cultured fetal ovarian model, the disintegration of germ cell nests and the assembly of primordial follicles can be improved by treating with an HDAC1 specific inhibitor Pyroxamide, and the injury caused by aspirin can be reversed. Therefore, the animal model established by the invention is novel, reliable, simple and convenient, meanwhile, the Pyroxamide has the effect of improving the reduction of the ovarian reserve function, and a new way is provided for preventing and treating the reduction of the fetal ovarian reserve function.

The invention belongs to the technical field of biological medicine, and relates to a thyroid-associated ophthalmopathy animal model construction method, which comprises: after constructing a pseudo-sterile animal model, firstly performing intragastric administration on the pseudo-sterile animal model with a coprophilous bacteria liquid of a thyroid-associated ophthalmopathy mild patient in a first stage, and injecting Ad-TSHR once in the latter half of the first stage; lastly, lastly, lastly, lastly, lastly, lastly, lastly, lastly, lastly, lastly, lastly, lastly, lastly, lastly, lastly, lastly, lastly, lastly, lastly, lastly, lastly, lastly, lastly, lastly, lastly, lastly, lastly, then in the third stage, the faecal bacteria liquid of the patient with the severe thyroid-associated eye disease is injected into the pseudo-sterile animal model, and Ad-TSHR is injected once in the second half process of the third stage; finally, Ad-TSHR is injected once in the latter half of the fourth stage; and obtaining the thyroid-associated eye disease animal model. Under the condition that the number of immunization times of the model is less, the morbidity of the model reaches up to 80%, and the death rate of the model is remarkably reduced.

The invention discloses a saponin component in pseudo-ginseng, and particularly relates to a novel medical application of ginsenoside 20S-Rf. Through cell and animal model research, the inventor finds that ginsenoside 20S-Rf has significant liver protection activity, can significantly improve the survival rate of acetaminophen (APAP) induced L02 cell injury, and has significant prevention and treatment effects (intragastric administration or intraperitoneal injection, 20 or 40 mg / kg) on mouse liver injury caused by APAP. The compound has obvious prevention and treatment effects on drug-induced liver injury and acute and chronic liver diseases caused by the drug-induced liver injury, and can be widely applied to liver protection drugs and health care products.

The invention belongs to the technical field of anti-cancer drugs, and particularly relates to a bipyridine derivative and a preparation method and application thereof, and a bipyridine ruthenium complex and a preparation method and application thereof. The invention provides a bipyridine derivative which has a structure as shown in a formula 1. The invention provides a bipyridine ruthenium complex which has a structure as shown in a formula 2. The BM-Cl provided by the invention has excellent anti-tumor activity through mouse tumor model caudal vein administration, and can be used as a PAD4 inhibitor. The BM-Ru1-Cl shows the excellent anti-tumor activity of dose dependence through intragastric administration of a mouse tumor model. Meanwhile, BM-Ru1-Cl can still play an anti-tumor role after being orally taken and absorbed into blood, and cannot be damaged by the stomach environment.

The invention discloses application of Pediococcus pentosaceus PPSJ001 or peptidoglycan of the Pediococcus pentosaceus PPSJ001 in preparation of a product for preventing or treating intestinal inflammatory diseases, and the Pediococcus pentosaceus PPSJ001 is Pediococcus pentosaceus. The invention further discloses a preparation method of the Pediococcus pentosaceus PPSJ001 and a preparation method of the Pediococcus pentosaceus PPSJ001. According to the application research of the pediococcus pentosaceus PPSJ001 and peptidoglycan thereof in DSS-induced acute and chronic colitis mouse models, prophylactic or therapeutic gavage can obviously reduce the inflammation degree, relieve weight loss, restore the colon length and improve pathological damage of colon tissue. The pediococcus pentosaceus PPSJ001 can be used for promoting the expression of tight junction proteins ZO-1 and Occludin and mucoprotein Muc2 and improving the barrier function of intestinal mucosa. The key functional component is cell wall peptidoglycan, and the peptidoglycan can remarkably relieve the colitis disease in vivo, promote polarization of macrophages to a CD206 + M2 type in vitro and improve expression of anti-inflammatory related genes Arg1. Based on the unique functions, the pediococcus pentosaceus PPSJ001 or peptidoglycan thereof can be coordinated or complemented with other micro-ecological regulation means, and has a wide application prospect in medicine preparation.

The application discloses a composition containing auro-thio-logic acid and polysulfide and application thereof, and belongs to the technical field of biological medicines, wherein the composition comprises auro-thio-logic acid and polysulfide. The application solves the defect that auro-thio-logic acid cannot efficiently inhibit cancer cell proliferation under normal physiological conditions by combining auro-thio-logic acid and polysulfide. When combined with polysulfide, auro-thio-logic acid can well inhibit the growth of tumors, indicating that auro-thio-logic acid and polysulfide can be applied as an anticancer drug combination. Moreover, the absorption of auro-thio-logic acid in tumor tissues can be adjusted by adjusting the type of polysulfide, so that the composition has good selectivity in anticancer in vivo. The composition has good stability and is not easy to be oxidized by air. The drug combination can also achieve an anticancer effect by oral (intragastric administration) mode, and is not limited to intraperitoneal or intravenous injection mode. Meanwhile, the drug combination also has good antibacterial effect.

The invention provides a construction method and application of a drug-induced mouse liver cancer model, and the construction method comprises the following steps: step S10, intragastric injection or intraperitoneal injection of a mouse with a DEN aqueous solution for 1-2 weeks, 5 times per week, to obtain a preliminary cancer-induced mouse; and step S20, carrying out tail intravenous injection on the mouse by using the DEN-loaded exosome solution for 4-6 weeks, and carrying out injection for 5 times per week to obtain the hepatocellular carcinoma-inducing mouse model. According to the scheme, firstly, a DEN aqueous solution is injected into a mouse through intragastric administration or intraperitoneal injection, so that the activity and the phagocytic function of liver macrophages are damaged, and the number of peritoneal macrophages is reduced; then, an exosome solution is injected into the caudal vein of the mouse, DEN is loaded in exosomes, when the exosomes enter the circulatory system through the caudal vein, the exosomes firstly flow through the liver to be metabolized, due to the fact that the activity of liver macrophages is invalid, liver cells can absorb the exosomes carrying the DEN, hepatocellular canceration is rapidly induced in the cell metabolism process, and the liver cancer is rapidly induced; and the modeling success rate of the mouse model is improved.